NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Bimekizumab for treating moderate to severe hidradenitis suppurativa ID6134

Provisional Stakeholder List

Consultees	**Commentators (no right to submit or appeal)**
Company • UCB Pharma (bimekizumab) Patient/carer groups • Action on Pain • African Health Policy Network • Black Health Agency for Equality • Changing Faces • Crohn's and Colitis UK • Hidradenitis Suppurativa Trust • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance Healthcare professional groups • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • St John's Institute of Dermatology • UK Clinical Pharmacy Association Others • Department of Health and Social Care • NHS England	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • AbbVie (adalimumab) • Amgen (adalimumab) • Biogen (adalimumab) • Celltrion Healthcare UK (adalimumab) • Fresenius Kabi (adalimumab) • Novartis (secukinumab) • Sandoz (adalimumab) Relevant research groups • British Skin Foundation • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Skin Group • Cochrane UK • Dermatrust

Consultees	Commentators (no right to submit or appeal)
	• Genomics England • MRC Clinical Trials Unit • National Institute for Health Research Associated Public Health groups • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.

